Institute of Medicine Suggests Changes to FDA Processes
The Institute of Medicine recommends major changes in the FDA’s regulatory process to help increase public health and safety with respect to pharmaceuticals, according to a statement by the IOM in the New England Journal of Medicine. The changes include:
- Giving the FDA greater access to administrative databases;
- Limiting conflicts of interest for members of advisory committees;
- Requiring reports of all clinical trials’ summary results;
- Increase in general appropriations to the FDA.
Post A Comment / Question